AGMB

AgomAb Therapeutics exploded higher during the regular session today, reaching a new 52-week high after the company announced regulatory alignment with the FDA on the design of its Phase 2b NOV-ERA study for Ontunisertib in fibrostenosing Crohn's disease. The positive market reaction follows the company's confirmation that the study will utilize a novel primary endpoint of endoscopic passability, a key milestone for the clinical-stage biotech. The stock is currently seeing mild pressure in after-hours trading, likely representing a period of profit-taking following the significant intraday rally.